|

Development of Camera Based Gait Quality Measure for Persons With Multiple Sclerosis

RECRUITINGSponsored by Shirley Ryan AbilityLab
Actively Recruiting
SponsorShirley Ryan AbilityLab
Started2024-07
Est. completion2025-07
Eligibility
Age18 Years – 75 Years
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT06516458

Summary

The purpose of this study is to develop a measurement of walking quality, called Gait Deviation Index (GDI) for people with Multiple Sclerosis (MS).

Eligibility

Age: 18 Years – 75 YearsHealthy volunteers accepted
Inclusion criteria:

* Diagnosis of relapsing form of MS (including relapsing-remitting MS and secondary progressive MS)
* Able to ambulate overground
* Relapse free for at least 1 month
* Age ≥18 and ≤ 75 years
* Participants using dalfampridine will be eligible if taking the same daily dose for at least 2 months prior to screening

Exclusion criteria:

\- Orthopedic injuries, fractures, surgeries or other conditions affecting locomotor function or weight bearing

Conditions4

Multiple SclerosisMultiple Sclerosis RelapseMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Secondary Progressive

Locations1 site

Shirley Ryan AbilityLab
Chicago, Illinois, 60611
Weena Dee, DPT312-238-7503wdee@sralab.org

Browse More Trials

Multiple Sclerosis trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.